Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
26.71 (1y: +58%)
Market Cap 15.01 B P/E(ttm) 34.70
Enterprise Value 18.13 B P/B 5.30
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry		 vs
history
Cash to Debt 0.236
GRFS's Cash to Debt is ranked lower than
93% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.43 vs. GRFS: 0.236 )
GRFS' s 10-Year Cash to Debt Range
Min: 0.03   Max: 0.31
Current: 0.24
0.03
0.31
Equity to Asset -0.171
GRFS's Equity to Asset is ranked lower than
72% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.47 vs. GRFS: -0.171 )
GRFS' s 10-Year Equity to Asset Range
Min: -0.21   Max: 0.31
Current: -0.17
-0.21
0.31
Interest Coverage 2.6
GRFS's Interest Coverage is ranked lower than
124% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 46.10 vs. GRFS: 2.6 )
GRFS' s 10-Year Interest Coverage Range
Min: 1   Max: No Debt
Current: 2.6
Z-Score: 3.38
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry		 vs
history
Operating margin (%) 25.20
GRFS's Operating margin (%) is ranked higher than
73% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.00 vs. GRFS: 25.20 )
GRFS' s 10-Year Operating margin (%) Range
Min: 9.7   Max: 25.2
Current: 25.2
9.7
25.2
Net-margin (%) 9.8
GRFS's Net-margin (%) is ranked higher than
61% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.30 vs. GRFS: 9.8 )
GRFS' s 10-Year Net-margin (%) Range
Min: 2.8   Max: 16.2
Current: 9.8
2.8
16.2
ROE (%) 13.7
GRFS's ROE (%) is ranked higher than
73% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. GRFS: 13.7 )
GRFS' s 10-Year ROE (%) Range
Min: 3   Max: 45.7
Current: 13.7
3
45.7
ROA (%) 4.6
GRFS's ROA (%) is ranked higher than
51% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.40 vs. GRFS: 4.6 )
GRFS' s 10-Year ROA (%) Range
Min: 0.9   Max: 10.3
Current: 4.6
0.9
10.3
ROC (Joel Greenblatt) (%) 36.20
GRFS's ROC (Joel Greenblatt) (%) is ranked lower than
124% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 14.00 vs. GRFS: 36.20 )
GRFS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 15.1   Max: 39.1
Current: 36.2
15.1
39.1
Revenue Growth (%) 19.4
GRFS's Revenue Growth (%) is ranked higher than
81% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.40 vs. GRFS: 19.4 )
GRFS' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 19.4
Current: 19.4
0
19.4
EBITDA Growth (%) 20.2
GRFS's EBITDA Growth (%) is ranked higher than
81% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.50 vs. GRFS: 20.2 )
GRFS' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 20.2
Current: 20.2
0
20.2
EPS Growth (%) 5.1
GRFS's EPS Growth (%) is ranked lower than
52% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.15 vs. GRFS: 5.1 )
GRFS' s 10-Year EPS Growth (%) Range
Min: 0   Max: 31.1
Current: 5.1
0
31.1
ยป GRFS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

GRFS Guru Trades in Q2 2012

Ron Baron 100,000 sh (unchged)
John Paulson 11,205,745 sh (unchged)
Steven Cohen Sold Out
Mario Gabelli Sold Out
» More
Q3 2012

GRFS Guru Trades in Q3 2012

Jim Simons 755,900 sh (New)
Mario Gabelli 27,820 sh (New)
Steve Mandel 219,774 sh (New)
Steven Cohen 344,160 sh (New)
John Paulson 16,385,799 sh (+46.23%)
Ron Baron 50,000 sh (-50%)
» More
Q4 2012

GRFS Guru Trades in Q4 2012

Steve Mandel 4,437,327 sh (+1919.04%)
John Paulson 20,179,935 sh (+23.16%)
Steven Cohen 420,947 sh (+22.31%)
Jim Simons 774,554 sh (+2.47%)
Mario Gabelli 23,968 sh (-13.85%)
Ron Baron 38,850 sh (-22.3%)
» More
Q1 2013

GRFS Guru Trades in Q1 2013

Jim Simons 918,154 sh (+18.54%)
Mario Gabelli 23,968 sh (unchged)
Steven Cohen Sold Out
Steve Mandel 4,433,955 sh (-0.08%)
John Paulson 20,054,379 sh (-0.62%)
Ron Baron 36,850 sh (-5.15%)
» More
» Details

Insider Trades

Latest Guru Trades with GRFS

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Steve Mandel 2012-12-31 Add 1919.04%0.67%$22.46 - $25.27 $ 26.7114%4437327
John Paulson 2012-12-31 Add 23.16%0.6%$22.46 - $25.27 $ 26.7114%20179935
Ron Baron 2012-12-31 Reduce -22.3%$22.46 - $25.27 $ 26.7114%38850
John Paulson 2012-09-30 Add 46.23%0.98%$9.66 - $22.92 $ 26.7147%16385799
Steve Mandel 2012-09-30 New Buy0.03%$9.66 - $22.92 $ 26.7147%219774
Mario Gabelli 2012-09-30 New Buy$9.66 - $22.92 $ 26.7147%27820
Ron Baron 2012-09-30 Reduce -50%$9.66 - $22.92 $ 26.7147%50000
Mario Gabelli 2012-06-30 Sold Out 0.0031%$7.8 - $9.68 $ 26.71206%0
Ron Baron 2012-03-31 Add 25%$5.38 - $7.8 $ 26.71325%100000
Steve Mandel 2011-12-31 Sold Out 0.37%$4.52727 - $6.06364 $ 26.71396%0
Steve Mandel 2011-09-30 New Buy0.37%$5.02 - $7.39 $ 26.71318%7067971
John Paulson 2011-09-30 Reduce -21.85%0.08%$5.02 - $7.39 $ 26.71318%11150000
Ron Baron 2011-09-30 New Buy$5.02 - $7.39 $ 26.71318%65000
John Paulson 2011-06-30 New Buy0.37%$6.29 - $6.95 $ 26.71309%14266995
Mario Gabelli 2011-06-30 New Buy$6.29 - $6.95 $ 26.71309%50583
Premium More recent guru trades are included for Premium Members only!!

Guru Investment Theses on Grifols SA

Baron Funds Comments on Grifols SA - Aug 30, 2012

From Baron Funds' second quarter commentary:

Grifols SA (GRFS) manufactures and sells plasma derivative healthcare products to hospitals and physicians globally. Grifols' NASDAQ-traded ADR increased over 24% during the quarter. Grifols' plasma proteins are an essential medical treatment for patients with primary immune deficiency, neurological diseases or hemophilia. Few companies can manufacture these treatments with a high degree of quality and consistency. Healthy demand for the product, coupled with a strong pricing environment, helped Grifols during the quarter.We continue to believe that Grifols will generate strong synergies from its 2011 acquisition of U.S.-based Talecris, and that Grifols will become significantly more profitable going forward. (Aaron Wasserman)
Check out Ron Baron latest stock trades

Top Ranked Articles about Grifols SA

Baron Funds Comments on Grifols SA
August 30, 2012
From Baron Funds' second quarter commentary: Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 34.70
GRFS's P/E(ttm) is ranked higher than
56% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.40 vs. GRFS: 34.70 )
GRFS' s 10-Year P/E(ttm) Range
Min: 16.44   Max: 36.07
Current: 34.7
16.44
36.07
P/B 5.30
GRFS's P/B is ranked lower than
99% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.41 vs. GRFS: 5.30 )
GRFS' s 10-Year P/B Range
Min: 2.02   Max: 5.3
Current: 5.3
2.02
5.3
P/S 2.70
GRFS's P/S is ranked lower than
89% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.40 vs. GRFS: 2.70 )
GRFS' s 10-Year P/S Range
Min: 1.61   Max: 3.79
Current: 2.7
1.61
3.79
PFCF 27.20
GRFS's PFCF is ranked lower than
128% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.35 vs. GRFS: 27.20 )
GRFS' s 10-Year PFCF Range
Min: 12.48   Max: 28.18
Current: 27.2
12.48
28.18
EV-to-EBIT 27.8
GRFS's EV-to-EBIT is ranked higher than
71% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.12 vs. GRFS: 27.8 )
GRFS' s 10-Year EV-to-EBIT Range
Min: 8.6   Max: 18
Current: 27.8
8.6
18
PEG 1.6
GRFS's PEG is ranked higher than
55% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.70 vs. GRFS: 1.6 )
GRFS' s 10-Year PEG Range
Min: 0   Max: 2
Current: 1.6
0
2

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 8.7
GRFS's Price/Net Current Asset Value is ranked lower than
53% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 12.40 vs. GRFS: 8.7 )
GRFS' s 10-Year Price/Net Current Asset Value Range
Min: 1.9   Max: 14.3
Current: 8.7
1.9
14.3
Price/Median PS Value 0.8
GRFS's Price/Median PS Value is ranked lower than
135% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.90 vs. GRFS: 0.8 )
GRFS' s 10-Year Price/Median PS Value Range
Min: 1.1   Max: 1.1
Current: 0.8
Earnings Yield (Greenblatt) 3.60
GRFS's Earnings Yield (Greenblatt) is ranked lower than
60% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. GRFS: 3.60 )
GRFS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.6   Max: 11.6
Current: 3.6
3.6
11.6

Business Description

Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain.
Company Website
Industry: Medical Instruments & Supplies
Compare:
Traded in other countries:GIFLF.USA, GIKLY.USA, GRFP.Spain, GRF.Spain

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial